August 2012
-
Bangladeshi pharmaceutical company Beximco Pharma has announced the resignation of Ahsanul Karim from the Board of Directors effective as April 3, 2013 and the appointment of Faheemul Huq as a Non-Executive Director. Beximco manufactures a… Read more . . .
-
According to Asthmapolis, the company has raised $5 million in Series A financing from The Social+Capital Partnership (“Social Capital”) that it will use to “deliver new innovations and services for its comprehensive solution of sensors,… Read more . . .
-
According to Insmed Incorporated, the US FDA has granted orphan drug designation to its Arikace liposomal amikacin for inhalation for the treatment of non-tuberculous mycobacteria (NTM) infections. Insmed is also developing Arikace for the treatment… Read more . . .
-
Device design and manufacturing company Nypro plans to build a device manufacturing facility in Waterford, Ireland and, according to the company, will hire 200 workers to staff the new plant. Nypro’s capabilities include injection molding… Read more . . .
-
Actavis says that it will launch 0.25 mg and 0.5 mg vials of its generic budesonide inhalation suspension immediately after the United States District Court for the District of New Jersey ruled that the products… Read more . . .
-
The UK’s National Institute for Health and Care Excellence (NICE) has issued a final guidance recommending Novartis’s Tobi Podhaler tobramycin DPI and Forest Lab’s Colobreathe colistimethate sodium DPI for the treatment of P. aeruginosa lung… Read more . . .
-
Pharmaceutical micronization specialist Micron Technologies has been acquired by private equity firm Arlington Capital Partners. Micron, which is based in Malvern, PA and has a facility in Dartford, UK, provides micronization services for both development… Read more . . .
-
According to the EMA, its Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion regarding the Labazenit budesonide/salmeterol dry powder inhaler. Belgian pharmaceutical company Laboratoires SMB applied to market the product, which… Read more . . .
-
The FDA has approved Novartis’s TOBI Podhaler tobramycin inhalation powder for the treatment of P. aeruginosa lung infections in cystic fibrosis patients. The agency’s Anti-Infective Drugs Advisory Committee (AIDAC) voted in favor of approval of… Read more . . .
-
The Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting regarding Breo Ellipta originally scheduled for March 7, 2013 has been rescheduled for April 17, 2013, from 8 am to 5 pm. The meeting was rescheduled due to… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland